Article: Ambien(R) (Zolpidem Tartrate) C(IV) Shown Safe and Effective With Longer-Term Use, Say Study Investigators at APA.

12-Week Trial Shows No Tolerance or Dose Escalation

Results of a 12-week, placebo-controlled clinical trial with Ambien(R) (zolpidem tartrate) C(IV), the leading prescription sleep aid in the U.S.,(1) demonstrated that the product safely and effectively treated insomnia intermittently with no evidence of tolerance or dose escalation -- complications often seen with extended use of older-generation sleep medications. The study, presented today at the 2004 American Psychiatric Association Annual Meeting, evaluated up to 5 nights of dosing per week, as needed, and underscored that the improvements in sleep provided by Ambien did not diminish over time and that ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!